[Adverse pulmonary drug effects].
Mazur
D
D
Institut für Klinische Pharmakologie und Toxikologie, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin.
Stahlmann
R
R
D000542:Alveolitis, Extrinsic Allergic / Q000139:chemically induced; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000139:chemically induced; D016084:Bronchoconstriction / Q000187:drug effects; D003371:Cough / Q000139:chemically induced; D018549:Cryptogenic Organizing Pneumonia / Q000139:chemically induced; D017576:Daptomycin / Q000009:adverse effects*; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D011654:Pulmonary Edema / Q000139:chemically induced; D011657:Pulmonary Eosinophilia / Q000139:chemically induced* / Q000188:drug therapy; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D013203:Staphylococcal Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D017576:Daptomycin; D008775:Methylprednisolone